$4.76
0.7518.7%
Last update: Nov 5, 5:37 PM
Gyre Therapeutics Inc (GYRE) Stock Price, Quote, News & History
GYRENASDAQ
HC Wainwright starts Gyre Therapeutics coverage with a Buy rating, citing hydronidone's $6 billion potential and strong fibrosis treatment pipeline.
You can purchase shares of Gyre Therapeutics (NASDAQ:GYRE) through any online brokerage.
Other companies in Gyre Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Gyre Therapeutics has a consensus price target of $17.00.
The stock price for Gyre Therapeutics (NASDAQ: GYRE) is $4 last updated November 5, 2026 at 5:37 PM EST.
There are no upcoming dividends for Gyre Therapeutics.
Gyre Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Gyre Therapeutics.
Gyre Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products...
